GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » Other Operating Expense

Endonovo Therapeutics (Endonovo Therapeutics) Other Operating Expense : $3.05 Mil (TTM As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics Other Operating Expense?

Endonovo Therapeutics's Other Operating Expense for the three months ended in Dec. 2023 was $0.79 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was $3.05 Mil.

Endonovo Therapeutics's quarterly Other Operating Expense declined from Jun. 2023 ($1.18 Mil) to Sep. 2023 ($0.47 Mil) but then increased from Sep. 2023 ($0.47 Mil) to Dec. 2023 ($0.79 Mil).

Endonovo Therapeutics's annual Other Operating Expense increased from Dec. 2021 ($2.29 Mil) to Dec. 2022 ($3.39 Mil) but then declined from Dec. 2022 ($3.39 Mil) to Dec. 2023 ($3.05 Mil).


Endonovo Therapeutics Other Operating Expense Historical Data

The historical data trend for Endonovo Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endonovo Therapeutics Other Operating Expense Chart

Endonovo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.03 3.01 2.29 3.39 3.05

Endonovo Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.61 1.18 0.47 0.79

Endonovo Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Endonovo Therapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Endonovo Therapeutics (Endonovo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc is an us-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.
Executives
Alan Brian Collier director, 10 percent owner, officer: CEO 6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann 10 percent owner, officer: President 6320 CANOGA AVENUE, WOODLAND HILLS CA 91367